BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA ® (motixafortide) through Gamida Cell Ltd. By Investing.com

“ BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell (OTC:)) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% “

“ BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC “

“ BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company’s pipeline and expansion “

“ Transactions enable significant reduction in BioLineRx’s operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases “

“ BioLineRx will provide further corporate updates on its Q3 results conference call, which is scheduled for November 25 at 8:30 am ET “

TEL AVIV, Israel, Nov. 21, 2024 /PRNewswire/ — BioLineRx Ltd . (NASDAQ: NASDAQ:) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Ayrmid Ltd. (“Ayrmid”), the parent company of Gamida Cell Ltd., today announced that on November 20, 2024, the companies entered into a license agreement for motixafortide (commercially sold in the U.S. as APHEXDA ^®), BioLineRx’s FDA-approved stem cell mobilization agent indicated in combination with filgrastim (G-CSF) for collection and subsequent autologous transplantation in patients with multiple myeloma.

Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize APHEXDA (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia. BioLineRx previously granted an exclusive license agreement to Gloria Biosciences for APHEXDA (motixafortide) in the Asia region.

In exchange for the license, BioLineRx will receive a $10 million upfront payment and is also eligible to receive up to an additional $87 million of potential commercial milestones, plus royalties ranging from 18% to 23% on net sales of APHEXDA.

Ayrmid will add APHEXDA to its commercial portfolio, which also includes Gamida Cell’s OMISIRGE ®, the first and only FDA-approved, nicotinamide (NAM)-modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant. As part of this transaction, Ayrmid expects to transition certain members of BioLineRx’s U.S.-based commercial organization, who will support both stem cell…